Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. (IRON) received a Rule 144 notice indicating that Atlas Venture Opportunity Fund I plans to sell common stock of the company. The notice covers 2,810 shares of common stock, with an aggregate market value of $224,940.50, to be sold through Merrill Lynch.
The shares relate to stock originally acquired on May 1, 2020 in a private placement for cash. At the time of the notice, Disc Medicine reports 38,392,844 shares of common stock outstanding. Additional recent sales by the same holder are referenced in an attached Table II.
Disc Medicine, Inc. (IRON) is the subject of a Form 144 notice filed for the account of Atlas Venture Fund X covering a proposed sale of 6,822 shares of common stock through Merrill Lynch on Nasdaq. The shares were acquired in a May 1, 2020 private placement for cash. A figure of 38,392,844 shares is listed for Disc Medicine’s common stock as of September 3, 2026; this is a baseline figure, not the amount being sold.
Disc Medicine, Inc. (IRON) received a notice under Rule 144 for a proposed resale of 513 shares of Common Stock by Atlas Venture Fund XII through Merrill Lynch. The shares were originally acquired from the issuer in a private placement on May 1, 2020 for cash, and the filing lists 38,392,844 shares outstanding as of September 2, 2026.
Disc Medicine, Inc. (symbol IRON) received a notice that Atlas Venture Opportunity Fund II plans to sell 22,099 shares of its common stock under Rule 144 through Merrill Lynch. The shares were acquired in a private placement on May 1, 2020. The notice lists an aggregate market value of $1,738,528.33 for the planned sale, with 38,392,844 shares of common stock outstanding and an approximate sale date of September 2, 2026 on Nasdaq.
Disc Medicine, Inc. (IRON) is the issuer of common stock that an affiliate, Atlas Venture Opportunity Fund I, has notified it plans to sell under Rule 144. The notice covers 26,552 shares of common stock, originally acquired in a private placement for cash on May 1, 2020, through broker Merrill Lynch.
Disc Medicine, Inc. (IRON) has a shareholder, Atlas Venture Fund X, that filed a notice of proposed resale of common stock under Rule 144. The shares were originally acquired from the issuer in a private placement for cash on May 1, 2020, and are expected to be sold through Merrill Lynch on Nasdaq. Additional recent sales over the prior three months are referenced in an attached table.
Disc Medicine, Inc. (IRON) reported that Chief Operating Officer Jonathan Yen-Wen Yu exercised stock options and sold the resulting common shares under a pre-arranged Rule 10b5-1 trading plan. On August 24, 2026, he exercised options for 300 shares of common stock at an exercise price of $13.50 per share and sold 300 shares at a weighted average price of $82.5333 per share, with sale prices ranging from $82.50 to $82.60. On August 25, 2026, he exercised options for an additional 8,796 shares at $13.50 per share and sold 8,796 shares at a weighted average price of $83.1164 per share, with sale prices ranging from $82.57 to $83.47. The options exercised were from a grant vesting in 48 equal monthly installments after December 29, 2022, and all reported trades were effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
Disc Medicine, Inc. (IRON) CEO and director John D. Quisel reported an option exercise and related share sales. On August 17, 2026, he exercised a stock option for 33,000 shares of common stock at an exercise price of $13.50 per share, reducing that option position to rights over 91,586 shares, with the option expiring on December 28, 2032. The same day, he sold an aggregate of 33,000 common shares in three open-market transactions at weighted average prices of $78.1061, $79.1952, and $79.8420 per share, each over stated price ranges. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
Disc Medicine insider John Quisel filed a notice to sell up to 33,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The shares relate to an exercise of stock options for cash on 08/17/2026. As context, 38,392,844 common shares were outstanding as of 08/17/2026; this is a baseline figure, not the amount being sold. Over the past three months, Quisel previously sold 33,000 shares on 07/13/2026 and 34,000 shares on 06/18/2026 under a Rule 10b5-1 trading plan.
Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen exercised stock options for 804 shares of common stock at an exercise price of $13.50 per share and sold 804 shares of common stock at a weighted average price of $82.6425 per share, with individual sale prices ranging from $82.54 to $82.83. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. Following the option exercise, he held 22,943 option shares tied to this grant, which vests in 48 equal monthly installments after December 29, 2022 and expires on December 28, 2032.